Multi-tailed lipids and uses thereof

Abstract

The present invention provides multi-tailed lipid compounds, and salts and stereoisomers thereof, and methods of preparing the compounds. Also provided are compositions including a compound of the invention and an agent (e.g., an siRNA, mRNA, plasmid DNA, small molecule, protein, peptide). The present invention also provides methods, and kits using the compositions for delivering an agent to a subject (e.g., to the liver, spleen, or lung of the subject) or cell and for treating and / or preventing a range of diseases, such as genetic diseases, proliferative diseases, hematological diseases, neurological diseases, immunological diseases, gastrointestinal diseases (e.g., liver diseases), respiratory diseases (e.g., lung diseases), painful conditions, psychiatric disorders, metabolic disorders, and spleen diseases.

Description

RELATED APPLICATIONS[0001]The present application claims priority under 35 U.S.C. §119(e) to U.S. provisional patent application, U.S. Ser. No. 61 / 839,616 filed Jun. 26, 2013, the entire contents of which is incorporated herein by reference.GOVERNMENT SUPPORT[0002]This invention was made with U.S. Government support under Grant No. R37-EB000244 awarded by the National Institutes of Health. The U.S. government has certain rights in this invention.BACKGROUND OF THE INVENTION[0003]The ability to silence genes via RNA interference (RNAi) was reported by Mello and Fire in 1998. See Fire et al., Nature (1998) 391:806-811. Since then, scientists have rushed to take advantage of the enormous therapeutic potential driven by targeted gene knockdown. This is evidenced by the fact that the first report of small interfering RNA (siRNA) mediated RNAi in human beings was reported only twelve years after the phenomenon was described in Caenorhabditis elegans. See Davis et al., Nature (2010) 464:106...

AI Technical Summary

Benefits of technology

The patent text describes how much of a compound described herein is needed to provide a therapeutic benefit in treating a condition or to delay or minimize symptoms associated with the condition. It also explains how much of the compound is needed to prevent the condition or its recurrence. The technical effect of the patent text is to provide a reference for how much of a compound to use in therapy or prophylaxis to achieve the desired outcome.

Problems solved by technology

However, the efficient delivery of siRNA is still a challenge in the development of siRNA therapeutics.

It is understood that the development of genetic drugs is slowed by the inability to deliver nucleic acids effectively in vivo.

However, despite promising data from ongoing clinical trials for the treatment of respiratory syncytial virus infection and liver cancers (see, e.g., Zamora et al., Am. J. Respir. Crit.

Despite the delivery successes met by some of these carriers, challenges to efficient delivery exist, including nanoparticle dissociation via serum proteins, cellular uptake, endosomal escape, and appropriate intracellular disassembly.

In spite of these efforts, the relationships between physicochemical properties of nanoparticles and biological barriers, and that between biological barriers and gene silencing activity remain unclear.

This lack of clarity has also resulted in poor in vitro-in vivo translation.

Images